Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published on October 21
Merck's $3 billion Virginia plant is just the beginning. This massive investment signals a fundamental shift towards domestic pharmaceutical production that could reshape the entire industry.
Recent global disruptions exposed critical vulnerabilities in drug supply chains. Companies leading the onshoring charge are positioning themselves as essential partners in America's healthcare security.
This isn't a quick trend but a structural shift requiring years of investment and development. Early movers in pharmaceutical onshoring could benefit from sustained tailwinds and government support.
Merck's massive $3 billion Virginia plant investment signals a fundamental shift towards domestic pharmaceutical production. This trend is driven by supply chain vulnerabilities exposed during recent global disruptions and growing government emphasis on healthcare security. We believe this creates a multi-year investment opportunity across the entire pharmaceutical manufacturing ecosystem.
This group includes both pharmaceutical giants making major onshoring investments and the supporting companies that enable domestic production. The theme spans drug manufacturers, industrial construction firms, specialised equipment providers, and logistics companies. It's a long-term play on rebuilding America's pharmaceutical infrastructure with potential for sustained growth.
These companies were handpicked by professional analysts based on their direct involvement in or benefit from the pharmaceutical onshoring trend. Each represents a different piece of the value chain, from major pharma companies leading the charge to essential service providers supporting the transition to domestic manufacturing.
Market capitalisation breakdown for the 'Pharma Onshoring' basket, highlighting total market cap and concentration among largest constituents.
MRK: $215.61B
PFE: $140.38B
LLY: $765.65B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
13 of 15 assets in this group are rated Buy by professional analysts.
